登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2025年4月30日（星期三）16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心 （一）会议召开时间：2025年4月30日（星期三）16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、 参加人员 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年4月23日（星期三）至4月29日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司投资者关系邮箱（ir@cansinotech.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）已于2025年3月26日发布2024年年度报告，并将于2025年4月30 日发布2025年第一季度报告。为便于广大投资者更全面深入地了解公司经营成果 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-013 康希诺生物股份公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com） 康希诺生物股份公司（以下简称"公司"）已于 2025 年 3 月 26 日发布 2024 年年度报告，并将于 2025 年 4 月 30 日发布 2025 年第一季度报告。为便于广大 投资者更全面深入地了解公司经营成果、财务状况，公司计划于 2025 年 4 月 30 日（星期三）16:00-17:00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资 者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度暨 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会 ...

Financial Performance - Total revenue for 2024 reached RMB 824.884 million, a significant increase from RMB 345.182 million in 2023, representing a growth of 139.2%[7] - The company reported an operating loss of RMB 403.39 million for 2024, an improvement compared to the operating loss of RMB 2.035 billion in 2023[7] - The company reported a gross profit of approximately RMB 580.5 million, recovering from a gross loss of RMB 876.0 million in 2023[63] - Revenue from the cerebrospinal meningitis vaccine product reached RMB 793.8 million in 2024, up from RMB 561.7 million in 2023[60] - Other income decreased by 44.5% to approximately RMB 109.5 million in 2024, primarily due to a reduction in government subsidies[64] - Financial income decreased from approximately RMB 563 million for the year ended December 31, 2023, to approximately RMB 222 million for the year ended December 31, 2024, primarily due to a reduction in financial income of approximately RMB 362 million[70] - Income tax expense for the year ended December 31, 2024, was approximately RMB 25 million, a decrease from approximately RMB 115 million in 2023, due to the write-off of deferred tax assets[71] Assets and Liabilities - Total assets decreased to RMB 7.958 billion in 2024 from RMB 9.319 billion in 2023, a decline of 14.6%[7] - The company’s total liabilities decreased to RMB 3.048 billion in 2024 from RMB 4.031 billion in 2023, a reduction of 24.4%[7] - The company’s total equity decreased to RMB 4.910 billion in 2024 from RMB 5.287 billion in 2023, a decline of 7.1%[7] - Non-current assets were reported at RMB 3.676 billion in 2024, down from RMB 4.138 billion in 2023, indicating a decrease of 11.1%[7] - Cash and cash equivalents decreased by 24% from approximately RMB 20,470 million as of December 31, 2023, to approximately RMB 15,565 million as of December 31, 2024, mainly due to cash outflows from operating activities and loan repayments[87] - Total current liabilities decreased from approximately RMB 25,918 million as of December 31, 2023, to approximately RMB 17,720 million as of December 31, 2024, reflecting a reduction in borrowings and other payables[87] Vaccine Development and Commercialization - The sales revenue from the four-valent meningococcal conjugate vaccine, Manhaixin®, and the bivalent meningococcal conjugate vaccine, Meinaixi®, amounted to approximately RMB 793.8 million in 2024, reflecting a year-on-year growth of 41.3%[9] - The company plans to expand the age range for the Manhaixin® vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, pending regulatory approval[9] - The company is set to launch a new product, a 13-valent pneumonia combined vaccine, in 2025, with the registration application already accepted in 2024[10] - The company has initiated Phase II/III clinical trials for a component DTP vaccine for adolescents and adults, and the registration application for the infant DTP vaccine has been accepted and prioritized for review[10] - The company has received over $19 million in funding for the development of a recombinant poliovirus vaccine, highlighting its role in improving global public health[12] - The company has obtained product registration for its vaccine in Indonesia and is conducting clinical trials for safety and immunogenicity in the 18-55 age group[13] - The company is collaborating with the National Institute of Biotechnology Malaysia to advance the development of an mRNA polyvalent influenza vaccine[13] - The company aims to establish long-term strategic partnerships based on its diverse product pipeline and is preparing for WHO prequalification to explore international procurement opportunities[14] - The company has transformed from a biotechnology company to a biopharmaceutical company, enhancing its self-sustaining capabilities as more products enter commercialization[14] - The company has a broad vaccine portfolio addressing over ten disease areas, with five commercialized products as of the report date[18] Research and Development - The company has improved the production technology of the investigational PCV13i vaccine, achieving good safety and immunogenicity in its Phase III clinical trial[29] - The company has received GMP certification for its Ad5-EBOV vaccine, which is the first Ebola vaccine approved in China for emergency use[28] - The company is advancing its pipeline of innovative vaccines, including mRNA-based influenza vaccines and other combination vaccines[20] - The company's new drug application for PCV13i has been accepted by the National Medical Products Administration, with expectations to obtain approval by 2025[30] - The PBPV vaccine, currently in Phase I clinical trials, shows good safety in adults and the elderly, with significant antibody responses observed[32] - The infant DTcP vaccine's new drug application has been accepted, with ongoing Phase III clinical trials and a summary report already obtained[35] - The tetanus vaccine has initiated Phase III clinical trials, with a new drug application expected to be approved in the first half of 2026[40] - The company has secured exclusive global rights from McMaster University for the development of a tuberculosis booster vaccine, with promising results from Phase I trials[41] - The PBPV vaccine aims to provide broader coverage than existing PPV23 and PCV13 products, targeting over 90 serotypes of pneumonia[31] - The company plans to strengthen clinical data for the infant DTcP vaccine in 2025 to expedite the review process[35] Corporate Governance - The company emphasizes the importance of independent judgment and oversight from its board members, enhancing corporate governance standards[106][107][108] - The board comprises members with diverse backgrounds in finance, healthcare, and management, contributing to a well-rounded decision-making process[109][110] - The company is focused on maintaining high standards of corporate governance through experienced independent directors and supervisors[112] - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix C1[120] - The company confirmed that all directors and supervisors complied with the standard code during the reporting period[121] - The company has established specific service contracts for all directors, with terms lasting until the current board's three-year term expires[133] - The nomination committee will identify suitable candidates to fill any board vacancies based on required skills and experience[134] - The company will continue to assess whether the roles of chairman and CEO should be separated in the future[129] - The company has maintained compliance with the requirement of having at least three independent non-executive directors on the board[130] - The board of directors is responsible for leading and monitoring the company, ensuring effective internal controls and risk management systems[136] Market Strategy and Expansion - The company plans to enhance its marketing efforts and strengthen professional academic promotion to increase public awareness of vaccines[57] - The company aims to expand its market presence in Southeast Asia, the Middle East, and Latin America through strategic acquisitions and partnerships[58] - The company is actively expanding its commercialization efforts, focusing on key clinical decision-makers and vaccination points to enhance market presence[55] - The company has a robust strategy for market expansion and product development in the biopharmaceutical sector[102] - The company is committed to providing high-quality, innovative, and accessible vaccines globally as part of its mission[183] Human Resources and Corporate Culture - The company has established a training program for new employees to enhance understanding of corporate culture and compliance[184] - The company aims to maintain a gender ratio among employees, with male employees accounting for 48.6% and female employees accounting for 51.4%[165] - The board currently consists of 7 members, including 3 executive directors, 1 non-executive director, and 3 independent non-executive directors, with 1 female director and 6 male directors[163] - The company is committed to achieving gender equality on the board as a long-term goal[164] - The company has established a whistleblowing policy that encourages reporting of misconduct, ensuring confidentiality and protection for whistleblowers[170] - The company emphasizes a corporate culture focused on innovation, quality, and responsibility, with a vision of "Innovation without end, a world without epidemics"[183]

康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 香港，2025年4月15日 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 （股份代號：6185） 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 董事會會議通告 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年4月29日（星 期 二）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年3月31日止三個月的第一季度業績及其發佈。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年4月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

后新冠时代，流脑疫苗能否撑起康希诺？ 以目前市场情况来看，在免疫规划内的AC群流脑多糖疫苗最受欢迎。据西南证券统计，2024FY （财政年度）脑膜炎疫苗批签发414批次，同比下降13%。其中，AC多糖疫苗占据主要份额，批签发 300批次，同比增长11%。 3月25日晚间，康希诺公布2024年年报，报告期内实现营收8.46亿元，同比增加137.01%；实现归母 净亏损3.79亿元，同比亏损减少74.45%；实现扣非净亏损4.41亿元，同比亏损减少72.61%。 连续两年业绩下滑后，2024年康希诺营收终于恢复正增长，亏损也进一步收窄。值得一提的是，其 两款流脑结合疫苗合计实现销售收入约7.94亿元，同比增长41.31%。 康希诺也表示，报告期内公司工作重点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的 研发，其四价结合流脑疫苗市场占有率不断提高，同时新冠疫情对公司的影响基本消除，带动公司营收 同比快速增长。 3月26日，康希诺股价高开低走。截至收盘，康希诺报57.81元/股，跌0.67%，当前市值为143.05亿 元。 康希诺的两款流脑疫苗分别是二价脑膜炎球菌多糖结合疫苗MCV2（商品名：美奈喜）、四价脑 ...

康希诺去年营收增长137.01%至8.46亿元，正开展四 价流脑结合疫苗出海 近日，康希诺发布2024年财报。披露公司去年营收增长137.01%至8.46亿元。净亏损3.79亿元。报告期内，公司工作重 点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的研发。 疫苗商业化端，公司持续搭建销售渠道，ACYW135 群脑膜炎球菌多糖结合疫苗（CRM197 载体）曼海欣®作为中国 市场上唯一的四价流脑结合疫苗，市场占有率不断提升，同时公司经营受全球公共卫生事件的影响已经基本消除。因 此，公司营业收入较去年同期快速增长，带动了公司经营成果的提升。 图片来源：企业公告截图 谈及脑膜炎球菌多糖结合疫苗商业化的推进，公告介绍，公司的 MCV4 曼海欣®和 MCV2 美奈喜®基于自身合成疫苗 技术平台，较现有产品做了大量的工艺改进和提升，切入国内脑膜炎球菌疫苗品种升级的市场机会，为中国市场提供 安全性更好、免疫原性更强的脑膜炎球菌疫苗产品。 对于婴幼儿组分百白破疫苗 DTcP进展，公告表示，目前国内在售的共纯化百白破疫苗的制造过程使用百日咳抗原共 纯化的工艺。公司在研百白破疫苗为组分百白破疫苗，每种百日咳抗原可以单独纯化， ...

智通财经APP讯，康希诺生物(06185)公布2024年业绩，收入约8.25亿元，较2023年增加139.0%。毛利约 5.8亿元，2023年毛损约8.76亿元。公司所有者应占年度亏损约3.79亿元，同比收窄74.45%;每股亏损1.53 元。 报告期内，公司继续推进流脑结合疫苗的商业化，截至本报告日期，曼海欣®已成功在中国中高端疫苗 市场商业化，渗透率持续提升。公司流脑结合疫苗产生销售收入约7.94亿元，较去年同期增长41.3%， 为公司稳定收入增长做出了贡献。 康希诺生物(06185)公布2024年业绩 公司所有者应占 年度亏损约3.79亿元 同比收窄74.45% 毛利由2023年的亏损改善及扭亏为盈至2024年的溢利，主要是由于：报告期内流脑疫苗产品收入增加以 及来自CDMO的新收入来源;及透过优化资源配置及提升营运效率，产能过剩成本以及存货及不动产、 工厂及设备减值损失大幅减少。 研发开支同比减少34.8%至4.16亿元，主要由于：优化研发人员结构，同时维持研发管线稳定推进，提 升整体营运效率;控制COVID-19相关管线的研发投入，同时优化资源配置，并专注于非COVID-19在研 疫苗;及集团更具潜 ...

康希诺2024年净亏损收窄74.45% 宣布与沙特 SPIMACO签署疫苗合作协议 而在发布年报的同时，康希诺宣布与沙特SPIMACO签署疫苗合作协议，双方将携手加速四价流脑结合 疫苗"曼海欣"进入沙特阿拉伯以及其他中东和北非地区市场，并推动联合研发与本地化生产体系建设。 记者注意到，这是"曼海欣"自去年12月获得印尼的注册证书之后的又一出海动态。此外，"曼海欣"已获 得印度尼西亚乌拉玛委员会食品、药品及化妆品评估机构授予的清真（Halal）认证。 根据年报，公司2024年收入增长有两方面原因，一是"曼海欣"作为中国市场上唯一的四价流脑结合疫 苗，产品渗透率不断提升，实现销量快速增长；二是公司经营受全球公共卫生事件的影响已基本消除。 值得注意的是，去年2月起，上药康希诺已经不再纳入集团合并范围，集团溢出成本较2023年同期大幅 下降。目前，"曼海欣""美奈喜"两款流脑结合疫苗是康希诺的营收主力，2024年共实现销售收入约7.94 亿元，同比增长41.31%，公司正在着重开展四价流脑结合疫苗的出海工作，主要以东南亚、中东、北 非、南美为目标区域，推动注册和商业化工作。 每经记者 林姿辰 每经编辑 董兴生 3月2 ...

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 824,884,000, an increase from RMB 345,182,000 in 2023[10] - Operating loss for the year was RMB (403,390,000), improved from a loss of RMB (2,035,182,000) in 2023[10] - Basic and diluted loss per share for 2024 was RMB (1.53), improved from RMB (6.01) in 2023[10] - The company achieved revenue of approximately RMB 824.9 million during the reporting period, representing a 139.0% increase compared to 2023[62] - Revenue from the cerebrospinal meningitis vaccine product reached RMB 793.8 million, up from RMB 561.7 million in 2023, indicating significant sales growth[63] - The company reported a gross profit of approximately RMB 580.5 million, recovering from a gross loss of RMB 876.0 million in 2023[66] - Other income decreased by 44.5% to approximately RMB 109.5 million, primarily due to a reduction in government subsidies and lower investment returns[67] Assets and Liabilities - Total assets decreased to RMB 7,958,132,000 from RMB 9,318,769,000 in 2023, representing a decline of approximately 14.6%[10] - Total liabilities decreased to RMB 3,048,260,000 from RMB 4,031,354,000 in 2023, a reduction of about 24.4%[10] - Total equity decreased to RMB 4,909,872,000 from RMB 5,287,415,000 in 2023, a decline of approximately 7.1%[10] - Current assets decreased to RMB 4,282,491,000 from RMB 5,180,828,000 in 2023, a reduction of about 17.3%[10] - Non-current assets decreased to RMB 3,675,641,000 from RMB 4,137,941,000 in 2023, a decline of approximately 11.2%[10] Research and Development - The company is focusing on new product development and market expansion strategies to enhance future performance[10] - The product registration application for the innovative 13-valent pneumococcal conjugate vaccine is expected to be submitted in 2024, with the aim of addressing unmet domestic market needs[13] - The recombinant pneumonia protein vaccine has shown promising preliminary results in Phase I clinical trials, covering at least 98% of pneumococcal serotypes[14] - The company is advancing its pipeline of innovative vaccines, including mRNA-based vaccines for influenza and other diseases[22] - The company has received positive results from the Phase I clinical trial of the PBPV vaccine, demonstrating good safety and significant antibody responses in adults and the elderly[35] - The company is developing an innovative tuberculosis booster vaccine, with positive results from Phase I trials indicating good safety and immune response[44] Market Strategy and Expansion - The company aims to establish long-term strategic partnerships based on its diverse product pipeline and is preparing for pre-qualification by the World Health Organization[17] - The product line strategically targets the large and underserved global market, including innovative vaccines and those aimed at replacing existing mainstream vaccines in China[20] - The company aims to expand its international market presence, particularly in Southeast Asia, the Middle East, and Latin America, through strategic acquisitions and partnerships[61] - The company is committed to providing innovative, high-quality, and accessible vaccines to meet global healthcare needs[20] Corporate Governance - The board consists of three executive directors, one non-executive director, and three independent non-executive directors[125] - The company has adopted the corporate governance code as per the Hong Kong Listing Rules Appendix C1, ensuring high standards of corporate governance[123] - The board believes that the current structure, where the chairman also serves as the CEO, benefits the company's operational efficiency[131] - The company will continue to review the effectiveness of its corporate governance structure[132] - The independent non-executive directors are considered independent throughout the reporting period[134] Clinical Trials and Approvals - The company has initiated Phase II/III clinical trials for the Tdcp vaccine for adolescents and adults, addressing a current market gap in China[40] - The company has received clinical trial approval for the DTcP-Hib-MCV4 combined vaccine and aims to meet market demand for combined vaccines[52] - The Phase I clinical trial for the recombinant shingles vaccine officially commenced in Canada in November 2023, with the first subject enrolled[47] - The company has received regulatory approval for its innovative recombinant vaccine products, demonstrating its commitment to research and development[119] Financial Management - Financial income decreased from approximately RMB 563 million for the year ended December 31, 2023, to approximately RMB 222 million for the year ended December 31, 2024, primarily due to a reduction in financial income of approximately RMB 362 million[73] - Income tax expense for the year ended December 31, 2024, was approximately RMB 25 million, a decrease from approximately RMB 115 million in 2023, due to the write-off of deferred tax assets[74] - Cash and cash equivalents decreased by 24.0% from approximately RMB 20,470 million as of December 31, 2023, to approximately RMB 15,565 million as of December 31, 2024, mainly due to cash outflows from operating activities and loan repayments[90] Management and Team - The company has established a strong operational team, significantly contributing to the rapid development and production of COVID-19 vaccines[105] - The management team has extensive experience in the biotechnology industry, contributing to strategic business development[120] - The company has attracted senior professionals from the vaccine industry, enhancing its expertise and capabilities in vaccine development[104] Legal and Compliance - The group faced a lawsuit from Belcher Farmaceutica Ltda. claiming damages of approximately RMB 197 million, but management believes the claim is unlikely to succeed[96] - The company has established written guidelines for employees regarding securities trading to prevent insider trading[124] - The company has implemented anti-corruption policies to enhance daily supervision and prevent unethical business practices[174] Employee Diversity and Inclusion - The company aims to maintain the current female representation on the board, with a long-term goal of achieving gender equality[169] - Among all employees, male employees account for 48.6% and female employees account for 51.4%, indicating a balanced gender diversity within the group[170] - The company will continue to maintain employee gender diversity and has measures in place to enhance gender diversity further[170]